NeuroPace, Inc. (NPCE) – What Are Investment Firms Thinking About This Stock?

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have been assigned an average recommendation of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $19.33.

A number of equities analysts have recently weighed in on NPCE shares. Guggenheim reiterated a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Mizuho assumed coverage on shares of NeuroPace in a research report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 target price on the stock. KeyCorp started coverage on shares of NeuroPace in a research note on Thursday, September 17th. They set an “overweight” rating and a $18.00 target price for the company. Weiss Ratings lowered shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of NeuroPace in a research report on Tuesday, September 15th.

NeuroPace Trading Down 1.8%

NASDAQ NPCE opened at $12.91 on Friday. NeuroPace has a 52 week low of $9.22 and a 52 week high of $19.60. The company has a 50 day moving average price of $13.84 and a 200 day moving average price of $15.14. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. The firm has a market cap of $443.12 million, a PE ratio of -22.65 and a beta of 1.86.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. The business had revenue of $22.83 million for the quarter, compared to analyst estimates of $22.61 million. As a group, sell-side analysts forecast that NeuroPace will post -0.67 EPS for the current fiscal year.

Institutional Trading of NeuroPace

Several hedge funds have recently modified their holdings of the stock. Legal & General Group Plc acquired a new position in shares of NeuroPace during the 2nd quarter worth about $41,000. SG Americas Securities LLC lifted its stake in NeuroPace by 52.9% during the first quarter. SG Americas Securities LLC now owns 11,640 shares of the company’s stock worth $153,000 after purchasing an additional 4,029 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in NeuroPace during the second quarter worth approximately $157,000. Bank of America Corp DE acquired a new position in NeuroPace in the second quarter valued at approximately $322,000. Finally, Canada Pension Plan Investment Board acquired a new position in NeuroPace in the second quarter valued at approximately $351,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About NeuroPace

NeuroPace, Inc is a medical device company focused on developing and commercializing therapies for people with drug-resistant epilepsy. Its principal product is the RNS System, an implantable responsive neurostimulation device designed to detect abnormal electrical activity in the brain and deliver targeted stimulation intended to prevent or reduce seizures.

The RNS System includes an implanted neurostimulator, leads placed at or near seizure-onset areas, and a programming and data-management platform used by healthcare professionals.